Who
Louise Frederika Kooij
Chief Accounting Officer
Company insider
Files Form 4 as: Chief Accounting Officer, NewAmsterdam Pharma Company.
In numbers
- Trades disclosed
- 101
- Buys
- 0
- Sells
- 16
- Bought
- $0
- Sold
- $36.6M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Jan 2024
- Last trade
- 20 Jul 2026
- Last filed
- 22 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Jul 2026filed 22 Jul 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code M | $298K25,000 at $11.90 | filing |
| 20 Jul 2026filed 22 Jul 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code M | $894K80,000 at $11.17 | filing |
| 20 Jul 2026filed 22 Jul 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $2.1M70,200 at $29.96 | filing |
| 20 Jul 2026filed 22 Jul 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 20 Jul 2026filed 22 Jul 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —80,000 at $0.00 | filing |
| 20 Jul 2026filed 22 Jul 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $990K31,885 at $31.05 | filing |
| 20 Jul 2026filed 22 Jul 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $92K2,915 at $31.71 | filing |
| 20 Jul 2026filed 22 Jul 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 20 Jul 2026filed 22 Jul 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —80,000 at $0.00 | filing |
| 20 Jul 2026filed 22 Jul 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code M | $298K25,000 at $11.90 | filing |
| 20 Jul 2026filed 22 Jul 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code M | $894K80,000 at $11.17 | filing |
| 20 Jul 2026filed 22 Jul 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $2.1M70,200 at $29.96 | filing |
| 20 Jul 2026filed 22 Jul 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $990K31,885 at $31.05 | filing |
| 20 Jul 2026filed 22 Jul 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $92K2,915 at $31.71 | filing |
| 22 Jun 2026filed 24 Jun 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code M | $273K25,000 at $10.90 | filing |
| 22 Jun 2026filed 24 Jun 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Code M | $179K15,000 at $11.90 | filing |
| 22 Jun 2026filed 24 Jun 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $1.2M39,700 at $30.20 | filing |
| 22 Jun 2026filed 24 Jun 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | NAMS NewAmsterdam Pharma CompanyBiotechnology | SEC FORM 4 Sold | $9,219300 at $30.73 | filing |
News
Head-To-Head Analysis: Rallybio (NASDAQ:RLYB) versus NewAmsterdam Pharma (NASDAQ:NAMS)NAMS · dailypolitical.com · 14 Oct 2026Analyzing NewAmsterdam Pharma (NASDAQ:NAMS) & Grifols (NASDAQ:GRFS)NAMS · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Louise Frederika Kooij; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.